SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Eli Lilly and Company (LLY) trades at a trailing P/E of 41.3, forward P/E of 26.8. Trailing earnings yield is 2.42%, forward earnings yield 3.73%. PEG 0.43 (Peter Lynch undervalued ≤1.0). Graham Number is $123.61.
Criteria proven by this page:
- VALUE (47/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 26.8 (down from trailing 41.3) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.43 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 2.42% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.73% as earnings recover.
- Analyst consensus target $1,243.95 (+34.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 86/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
47/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LLY
Valuation Multiples
P/E (TTM)41.3
Forward P/E26.8
PEG Ratio0.43
Forward PEG0.54
P/B Ratio32.09
P/S Ratio13.74
EV/EBITDA33.3
Per Share Data
EPS (TTM)$22.98
Forward EPS (Est.)$34.41
Book Value / Share$29.55
Revenue / Share$72.58
FCF / Share$9.99
Yields & Fair Value
Earnings Yield2.42%
Forward Earnings Yield3.73%
Dividend Yield0.66%
Graham Number$123.61
SharesGrow IV$919.68 (-0.3%)
Analyst Target$1,243.95 (+34.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
29.6 |
2.08 |
5.78 |
3.82 |
2.67% |
| 2017 |
-435.3 |
4.04 |
7.66 |
4.45 |
2.47% |
| 2018 |
36.8 |
-0.02 |
12.10 |
5.53 |
1.94% |
| 2019 |
15.1 |
0.09 |
48.27 |
5.64 |
1.91% |
| 2020 |
26.1 |
-1.02 |
28.63 |
6.58 |
1.66% |
| 2021 |
47.2 |
-4.92 |
29.34 |
9.30 |
1.17% |
| 2022 |
55.7 |
4.52 |
32.64 |
12.18 |
1.02% |
| 2023 |
100.0 |
-8.88 |
48.67 |
15.36 |
0.78% |
| 2024 |
65.7 |
0.65 |
48.99 |
15.44 |
0.67% |
| 2025 |
46.8 |
0.49 |
36.37 |
14.81 |
0.56% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.58 |
$21.22B |
$2.74B |
12.9% |
| 2017 |
$-0.19 |
$19.97B |
$-204.1M |
-1% |
| 2018 |
$3.13 |
$21.49B |
$3.23B |
15% |
| 2019 |
$4.96 |
$22.32B |
$8.32B |
37.3% |
| 2020 |
$6.79 |
$24.54B |
$6.19B |
25.2% |
| 2021 |
$6.12 |
$28.32B |
$5.58B |
19.7% |
| 2022 |
$6.90 |
$28.54B |
$6.24B |
21.9% |
| 2023 |
$5.80 |
$34.12B |
$5.24B |
15.4% |
| 2024 |
$11.71 |
$45.04B |
$10.59B |
23.5% |
| 2025 |
$22.95 |
$65.18B |
$20.64B |
31.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$34.43 |
$30.46 – $37.40 |
$81.69B |
$78.74B – $83.17B |
17 |
| 2027 |
$42.02 |
$36.45 – $45.04 |
$94.82B |
$85.3B – $102.57B |
17 |
| 2028 |
$49.21 |
$42.81 – $55.85 |
$106.38B |
$106.1B – $106.65B |
9 |
| 2029 |
$55.40 |
$51.15 – $60.39 |
$117.17B |
$110.27B – $125.29B |
3 |
| 2030 |
$60.97 |
$56.30 – $66.47 |
$126.59B |
$119.14B – $135.37B |
3 |
